

2016-2017

THÈSE

pour le

DIPLÔME D'ÉTAT DE DOCTEUR EN MÉDECINE

Qualification en Gynécologie Obstétrique

Evaluation of predictor risk factors and calculation of a margin index for ipsilateral invasive recurrence following treatment of DCIS: a Fifteen year observational study.

Evaluation des facteurs de risque péjoratifs et calcul d'un index de marge dans le risque de récurrence infiltrante homolatérale après traitement d'un Carcinome in Situ du sein : une étude observationnelle de 15 ans.

RICHARD BROOKS Marion

Née le 22/07/1987 à Vendôme (41)

Sous la direction du Dr Anne Sophie OGER

Membres du jury

Monsieur le Professeur DESCAMPS Philippe		Président
Madame le Docteur OGER Anne Sophie		Directeur
Monsieur le Professeur CLASSE Jean Marc		Membre
Monsieur le Docteur CAPITAIN Olivier		Membre
Madame le Docteur MESGOUEZ NEBOUT Nathalie		Membre

Soutenue publiquement le :
13 Janvier 2017



UFR SANTÉ

ENGAGEMENT DE NON PLAGIAT

Je, soussigné(e) **RICHARD BROOKS Marion**
déclare être pleinement conscient(e) que le plagiat de documents ou d'une
partie d'un document publiée sur toutes formes de support, y compris l'internet,
constitue une violation des droits d'auteur ainsi qu'une fraude caractérisée.
En conséquence, je m'engage à citer toutes les sources que j'ai utilisées
pour écrire ce rapport ou mémoire.

signé par l'étudiant(e) le **15/12/2016**

LISTE DES ENSEIGNANTS DE L'UFR SANTÉ D'ANGERS

Directeur de l'UFR : Pr Isabelle RICHARD

Directeur adjoint de l'UFR et directeur du département de pharmacie : Pr Frédéric LAGARCE

Directeur du département de médecine : Pr Nicolas LEROLLE

PROFESSEURS DES UNIVERSITÉS

ABRAHAM Pierre	Physiologie	Médecine
ASFAR Pierre	Réanimation	Médecine
AUBE Christophe	Radiologie et imagerie médicale	Médecine
AUDRAN Maurice	Rhumatologie	Médecine
AZZOUZI Abdel Rahmène	Urologie	Médecine
BARON-HAURY Céline	Médecine générale	Médecine
BARTHELAIX Annick	Biologie cellulaire	Médecine
BATAILLE François-Régis	Hématologie ; transfusion	Médecine
BAUFRETON Christophe	Chirurgie thoracique et cardiovasculaire	Médecine
BEAUCHET Olivier	Gériatrie et biologie du vieillissement	Médecine
BENOIT Jean-Pierre	Pharmacotechnie	Pharmacie
BEYDON Laurent	Anesthésiologie-réanimation	Médecine
BIZOT Pascal	Chirurgie orthopédique et traumatologique	Médecine
BONNEAU Dominique	Génétique	Médecine
BOUCHARA Jean-Philippe	Parasitologie et mycologie	Médecine
BRIET Marie	Pharmacologie	Médecine
CAILLIEZ Eric	Médecine générale	Médecine
CALES Paul	Gastroentérologie ; hépatologie	Médecine
CAMPONE Mario	Cancérologie ; radiothérapie	Médecine
CAROLI-BOSC François-Xavier	Gastroentérologie ; hépatologie	Médecine
CHABASSE Dominique	Parasitologie et mycologie	Médecine
CHAPPARD Daniel	Cytologie et histologie	Médecine
CONNAN Laurent	Médecine générale	Médecine
COUTANT Régis	Pédiatrie	Médecine
COUTURIER Olivier	Biophysique et médecine nucléaire	Médecine
CUSTAUD Marc-Antoine	Physiologie	Médecine
DARSONVAL Vincent	Chirurgie plastique, reconstructrice et esthétique	Médecine
DE BRUX Jean-Louis	Chirurgie thoracique et cardiovasculaire	Médecine
DESCAMPS Philippe	Gynécologie-obstétrique	Médecine
DIQUET Bertrand	Pharmacologie	Médecine
DUVAL Olivier	Chimie thérapeutique	Pharmacie
DUVERGER Philippe	Pédopsychiatrie	Médecine
ENON Bernard	Chirurgie vasculaire ; médecine vasculaire	Médecine
EVEILLARD Mathieu	Bactériologie-virologie	Pharmacie
FANELLO Serge	Épidémiologie ; économie de la santé et prévention	Médecine
FAURE Sébastien	Pharmacologie physiologie	Pharmacie
FOURNIER Henri-Dominique	Anatomie	Médecine
FURBER Alain	Cardiologie	Médecine
GAGNADOUX Frédéric	Pneumologie	Médecine
GARNIER François	Médecine générale	Médecine
GARRE Jean-Bernard	Psychiatrie d'adultes	Médecine
GOHIER Bénédicte	Psychiatrie d'adultes	Médecine
GRANRY Jean-Claude	Anesthésiologie-réanimation	Médecine
GUARDIOLA Philippe	Hématologie ; transfusion	Médecine
GUILLET David	Chimie analytique	Pharmacie

HAMY Antoine	Chirurgie générale	Médecine
HUEZ Jean-François	Médecine générale	Médecine
HUNAUT-BERGER Mathilde	Hématologie ; transfusion	Médecine
IFRAH Norbert	Hématologie ; transfusion	Médecine
JARDEL Alain	Physiologie	Pharmacie
JEANNIN Pascale	Immunologie	Médecine
JOLY-GUILLOU Marie-Laure	Bactériologie-virologie ; hygiène hospitalière	Médecine
LACOURREYE Laurent	Oto-rhino-laryngologie	Médecine
LAGARCE Frédéric	Biopharmacie	Pharmacie
LARCHER Gérald	Biochimie et biologie moléculaires	Pharmacie
LASOCKI Sigismond	Anesthésiologie-réanimation	Médecine
LAUMONIER Frédéric	Chirurgie infantile	Médecine
LEFTHERIOTIS Georges	Physiologie	Médecine
LEGRAND Erick	Rhumatologie	Médecine
LERMITE Emilie	Chirurgie générale	Médecine
LEROLLE Nicolas	Réanimation	Médecine
LUNEL-FABIANI Françoise	Bactériologie-virologie ; hygiène hospitalière	Médecine
MARCHAIS Véronique	Bactériologie-virologie	Pharmacie
MARTIN Ludovic	Dermato-vénéréologie	Médecine
MENEI Philippe	Neurochirurgie	Médecine
MERCAT Alain	Réanimation	Médecine
MERCIER Philippe	Anatomie	Médecine
MILEA Dan	Ophthalmologie	Médecine
PAPON Nicolas	Parasitologie mycologie	Pharmacie
PASSIRANI Catherine	Chimie générale	Pharmacie
PELLIER Isabelle	Pédiatrie	Médecine
PICHARD Eric	Maladies infectieuses ; maladies tropicales	Médecine
PICQUET Jean	Chirurgie vasculaire ; médecine vasculaire	Médecine
PODEVIN Guillaume	Chirurgie infantile	Médecine
PROCACCIO Vincent	Génétique	Médecine
PRUNIER Fabrice	Cardiologie	Médecine
REYNIER Pascal	Biochimie et biologie moléculaire	Médecine
RICHARD Isabelle	Médecine physique et de réadaptation	Médecine
RICHOMME Pascal	Pharmacognosie	Pharmacie
RODIEN Patrice	Endocrinologie, diabète et maladies métaboliques	Médecine
ROHMER Vincent	Endocrinologie, diabète et maladies métaboliques	Médecine
ROQUELAURE Yves	Médecine et santé au travail	Médecine
ROUGE-MAILLART Clotilde	Médecine légale et droit de la santé	Médecine
ROUSSEAU Audrey	Anatomie et cytologie pathologiques	Médecine
ROUSSEAU Pascal	Chirurgie plastique, reconstructrice et esthétique	Médecine
ROUSSELET M.-Christine	Anatomie et cytologie pathologiques	Médecine
ROY Pierre-Marie	Thérapeutique ; médecine d'urgence	Médecine
SAINT-ANDRE Jean-Paul	Anatomie et cytologie pathologiques	Médecine
SAULNIER Patrick	Biophysique pharmaceutique et biostatistique	Pharmacie
SENTILHES Loïc	Gynécologie-obstétrique	Médecine
SERAPHIN Denis	Chimie organique	Pharmacie
SUBRA Jean-François	Néphrologie	Médecine
UGO Valérie	Hématologie ; transfusion	Médecine
URBAN Thierry	Pneumologie	Médecine
VENIER Marie-Claire	Pharmacotechnie	Pharmacie
VERNY Christophe	Neurologie	Médecine
WILLOTEAUX Serge	Radiologie et imagerie médicale	Médecine
ZAHAR Jean-Ralph	Bactériologie-virologie ; hygiène hospitalière	Médecine
ZANDECKI Marc	Hématologie ; transfusion	Médecine

MAÎTRES DE CONFÉRENCES

ANNAIX Véronique	Biochimie et biologie moléculaires	Pharmacie
ANNWEILER Cédric	Gériatrie et biologie du vieillissement	Médecine
AUGUSTO Jean-François	Néphrologie	Médecine
BAGLIN Isabelle	Pharmaco-chimie	Pharmacie
BASTIAT Guillaume	Biophysique et biostatistique	Pharmacie
BEAUVILLAIN Céline	Immunologie	Médecine
BELIZNA Cristina	Médecine interne	Médecine
BELLANGER William	Médecine générale	Médecine
BENOIT Jacqueline	Pharmacologie et pharmacocinétique	Pharmacie
BIGOT Pierre	Urologie	Médecine
BLANCHET Odile	Hématologie ; transfusion	Médecine
BOISARD Séverine	Chimie analytique	Pharmacie
BOURSIER Jérôme	Gastroentérologie ; hépatologie	Médecine
CAPITAIN Olivier	Cancérologie ; radiothérapie	Médecine
CASSEREAU Julien	Neurologie	Médecine
CHEVAILLER Alain	Immunologie	Médecine
CHEVALIER Sylvie	Biologie cellulaire	Médecine
CLERE Nicolas	Pharmacologie	Pharmacie
CRONIER Patrick	Chirurgie orthopédique et traumatologique	Médecine
DE CASABIANCA Catherine	Médecine générale	Médecine
DERBRE Séverine	Pharmacognosie	Pharmacie
DESHAYES Caroline	Bactériologie virologie	Pharmacie
DINOMAIS Mickaël	Médecine physique et de réadaptation	Médecine
DUCANCELLE Alexandra	Bactériologie-virologie ; hygiène hospitalière	Médecine
FERRE Marc	Biologie moléculaire	Médecine
FLEURY Maxime	Immunologie	Pharmacie
FORTRAT Jacques-Olivier	Physiologie	Médecine
HELESBEUX Jean-Jacques	Chimie organique	Pharmacie
HINDRE François	Biophysique	Médecine
JEANGUILLAUME Christian	Biophysique et médecine nucléaire	Médecine
JOUSSET-THULLIER Nathalie	Médecine légale et droit de la santé	Médecine
KEMPF Marie	Bactériologie-virologie ; hygiène hospitalière	Médecine
LACOEUILLE Franck	Biophysique et médecine nucléaire	Médecine
LANDREAU Anne	Botanique	Pharmacie
LE RAY-RICHOMME Anne-Marie	Valorisation des substances naturelles	Pharmacie
LEPELTIER Elise	Chimie générale Nanovectorisation	Pharmacie
LETOURNEL Franck	Biologie cellulaire	Médecine
LIBOUBAN Hélène	Histologie	Médecine
MALLET Sabine	Chimie Analytique et bromatologie	Pharmacie
MAROT Agnès	Parasitologie et mycologie médicale	Pharmacie
MAY-PANLOUP Pascale	Biologie et médecine du développement et de la reproduction	Médecine
MESLIER Nicole	Physiologie	Médecine
MOUILLIE Jean-Marc	Philosophie	Médecine
NAIL BILLAUD Sandrine	Immunologie	Pharmacie
PAPON Xavier	Anatomie	Médecine
PASCO-PAPON Anne	Radiologie et imagerie médicale	Médecine
PECH Brigitte	Pharmacotechnie	Pharmacie
PENCHAUD Anne-Laurence	Sociologie	Médecine
PETIT Audrey	Médecine et santé au travail	Médecine
PIHET Marc	Parasitologie et mycologie	Médecine
PRUNIER Delphine	Biochimie et biologie moléculaire	Médecine
RIOU Jérémie	Biostatistique	Pharmacie
ROGER Emilie	Pharmacotechnie	Pharmacie
SCHINKOWITZ Andréas	Pharmacognosie	Pharmacie
SIMARD Gilles	Biochimie et biologie moléculaire	Médecine

TANGUY-SCHMIDT Aline
TRICAUD Anne
TURCANT Alain

Hématologie ; transfusion
Biologie cellulaire
Pharmacologie

Médecine
Pharmacie
Médecine

AUTRES ENSEIGNANTS

AMIARD Stéphane
AUTRET Erwan
BRUNOIS-DEBU Isabelle
CAVAILLON Pascal
CHIKH Yamina
FISBACH Martine
LAFFILHE Jean-Louis
LETERTRE Elisabeth
O'SULLIVAN Kayleigh

Informatique
Anglais
Anglais
Pharmacie Industrielle
Économie-Gestion
Anglais
Officine
Coordination ingénierie de formation
Anglais

Médecine
Médecine
Pharmacie
Pharmacie
Médecine
Médecine
Pharmacie
Médecine
Médecine

REMERCIEMENTS

A Monsieur le Professeur Philippe DESCAMPS,
Vous me faites l'honneur de présider ce jury. J'ai apprécié travailler dans votre service tout au long de mon internat. Soyez assuré de mon plus profond respect.

A Madame le Docteur Anne Sophie OGER,
Je te remercie de m'avoir fait confiance en me proposant de travailler avec toi sur cette étude. Mon semestre à tes côtés au centre Paul Papin a été riche en apprentissage tant sur le plan chirurgical que sur le plan humain. T'avoir comme directrice de thèse est une chance et travailler avec toi est un réel plaisir (vive RFM au bloc !). Un grand merci à toi.

A Monsieur le Professeur Jean Marc CLASSE,
Pour avoir accepté de juger ce travail et de siéger à ce jury. Recevez toute ma considération.

A Monsieur le Docteur Olivier CAPITAIN,
Pour votre retour d'expérience en oncologie et votre pédagogie lors des séances de bibliographie au centre Paul Papin, pour avoir accepté de juger ce travail, je vous remercie.

A Madame le Docteur Nathalie MESGOUZ NEBOUT,
Je te remercie d'avoir accepté de participer à ce jury, j'y tenais beaucoup. J'ai beaucoup aimé travailler à tes côtés lors de mon semestre en radiothérapie, notamment lors des séances de curiethérapie (Sam Smith en salle de traitement) tu m'as beaucoup appris sur la prise en charge des patientes de cancérologie.

A tous les Gynécologues Obstétriciens du CHU de Angers. Veuillez trouver ici ma sincère reconnaissance pour m'avoir appris à travers votre expérience, et continuer de m'apprendre ce merveilleux métier de Gynécologue Obstétricien.

A Monsieur le Docteur Guillaume LEGENDRE,
Depuis ton arrivée à la maternité de Angers, tu n'as eu de cesse de nous instruire, de nous pousser dans notre réflexion en tant que médecin. Tu m'as appris et donné le goût du travail universitaire. Tu es toujours là pour nous encourager. Je te remercie profondément.

A toute l'équipe de sages femmes de la maternité du CHU de Angers,
Pour votre patience et vos encouragements tout du long de ma formation en salle de naissance, aux UGO et en grossesse à risque.

A Monsieur le Dr Apollinaire KARIRISI,
A toute l'équipe du service de la maternité de Laval pour votre gentillesse et votre patience lors de mon passage pour mon premier semestre d'internat. Vous m'avez fait découvrir mes premiers accouchements.

A tous les Gynécologues Obstétriciens de la maternité du Mans, pour votre gentillesse et bienveillance lors de mon arrivée dans une maternité de niveau 3.

A tous les chirurgiens du centre ICO Paul Papin, pour m'avoir accueillie dans le centre au sein de ce semestre de chirurgie. Au Dr Nicolas PAILLOCHER pour son engouement pour la formation des internes, à travers les blocs, les séances de bibliographie et les cours d'anatomie du mardi.

A toute l'équipe de radiothérapie du centre ICO Paul Papin, pour votre bienveillance et pour m'avoir fait découvert votre spécialité.

A Monsieur le Professeur HAMY pour votre gentillesse lors de mon passage dans votre service de chirurgie viscérale du CHU de Angers. A toute l'équipe de Chirurgie Viscérale du CHU de Angers, pour m'avoir accueillie pendant six mois dans votre famille.

A toute l'équipe de Chirurgie Viscérale de l'hôpital du Mans, pour m'avoir fait découvrir la chirurgie viscérale et bariatrique et les bases de la chirurgie générale.

REMERCIEMENTS

A tous mes co-internes de Gynécologie Obstétrique, Fanny, Léa, Sarah A, Sarah T, Diane, Charlyne, Amélie, Vincent, Claire, Chloé, Véronique et Caroline. A nos soirées raclettes, crêpes et autres...

A Romain pour ta bonne humeur, on va prendre un verre ?! A Constance mon coach de footing autour du Lac St Nicolas en refaisant le monde, à Joséphine pour ce semestre au Mans et notre amitié qui a suivi, bon vent sur ton paddle !

A mes co internes de radiothérapie Pierre G, Pierre T, Florence, Julie, et Blandine,
A tous nos tite, les séquences « les professionnels », « la grosse berque » et autres délires...

A tous mes cointernes de Chirurgie Viscérale du Mans, Adeline, et du CHU Tchala, Marine, Sandra, Julien et Julie

A mes professeurs de lycée, à Monsieur ROUSSEAU (histoire géo) pour l'ouverture sur le monde actuel que vous nous transmettiez

A Monsieur Jaquin, professeur de mathématiques au Lycée Pasteur, pour votre pédagogie, votre foi dans ma maturité et ma capacité à réussir dans la vie...

A mes professeurs de collège, à Monsieur Jacques qui m'a donné le goût de la langue de Shakespeare

A mes instituteurs de maternelle et primaire pour m'avoir transmis et instruit les matières fondamentales à mon éducation.

A mes professeurs de violoncelle au Conservatoire de Musique et de Danse de Angers Monsieur ZANOTTI et de Besançon Monsieur ADAM pour m'avoir transmis votre passion de la musique et votre rigueur dans le travail au cours de toutes ces années.

REMERCIEMENTS

A tous les Lavallois, sans qui mon internat n'aurait jamais été le même si je ne vous avais pas rencontré lors de ce premier semestre incroyable que nous avons passé à l'internat de Laval, « Laval la vie » ! aux soirées du jeudi, au Fourchathlon ;

A Sophie et Antoine « les Brangeois », bon courage pour l'organisation de cette grande célébration qu'est votre mariage et tous mes vœux de bonheur.

A Rosen pour ces deux années en colloc passées ensemble (Black Top pour le ménage), à toutes nos soirées à thème à 50 personnes dans l'appart, avec le voisin « il n'a pas aimé ma préférence », à l'Irlande et surtout à la péninsule de Dingle « est ce que ça peut être pire » ?!... Je te souhaite d'être heureuse en Belgique

A Laure et Camille, à notre colloc aux Fourches et à Nicolas et Christophe qui partagent leurs vies

A Fedoua et Jacques que votre expérience en Nouvelle Calédonie vous apporte du bonheur.

A Julien, Anais et Chloé, A Elsa, Fabrice, Jules et Jeanne un grand merci pour tous ces moments passés ensemble

A Marion, que ta nouvelle vie à la Réunion remplisse toutes tes attentes

A Pierre T et Mélanie, tous mes vœux de bonheur pour votre mariage ! je tacherai de repartir avec la veste de quelqu'un d'autre à la fin de la soirée

To all my friends from the USA, Steph and John, Mark, Emmet, Erica, Tanis and Erica, Parris, Jon, Jess, Laura and Eric

To Brandon, citizen of the world!

To Danny and Emily, you guys are one of the best, we can't wait to visit you in San Francisco!!

A tous les copains de Besançon, Pierre S, Charlotte (les parents) Antoine (le blond) et Emilie qui partagent sa vie, Sophie O, Marie Justine et Alice pour toutes nos années à la faculté de Médecine de Besançon, à la BU mais surtout nos weekend ski, weekend beauf', weekend à Vouglan, à la Cabane, les soirées dans nos différents appart respectifs

Au Pink Lady, Hélène, Lucile, Coralie et Elena, depuis dix ans déjà que nous nous connaissons, et à Romain, Antoine, Alex et Erwann qui partagent leurs vies, vous avez été témoins des différentes étapes de ma vie des débuts à la fac, les choix de l'internat (« l'effet papillon ») jusqu'à être témoins lors de mon mariage. Vous avoir comme meilleures amies est une chance et même si la distance nous sépare nous sommes et demeurerons toujours un groupe extraordinaire, ma famille de cœur.

REMERCIEMENTS

A ma famille Tati Anne Marie (marraine la bonne fée), Thierry, Anaïs, Guillaume (nos vacances passés ensemble, la fourmière en Aveyron et le poulailler à Avignon) et à Clarisse et Malo qui le comble de joie
A mon tonton John Peter Colonel Mac Namara qui reste parmi nous d'où qu'il soit.

A Martine et Christian à tous les nouveaux ans passés avec vous depuis aussi longtemps que je me souviens, à vos parties de tarot arrosées de champagne avec papa, maman et Jean Pierre.

A Roberte et Didier, à Eliane et Claude mon parrain, à Jérôme, Ilaria et Lukas.

A mon grand-père et à ma grand-mère qui m'ont toujours soutenue, qui n'ont eu de cesse de prier lors de chacun de mes examens à la faculté de médecine.

A mon papi.

To Alex, Brenda, (and our weekend in Portsmouth, NH) and Katie my new brothers and sisters in law.
To Sheri and Alan, my parents in law. Since I met you, you always bring me as part of the Brook's family. You are great people, you were so nice and welcoming with me since we first met.

A mes deux grands frères Arnaud et Simon qui depuis ma naissance remplissent leur rôle de grand frère à merveille, à toutes nos chamailleries petits, nos retrouvailles jeunes adultes. À Alix et Fanny qui les remplissent de joie en partageant leurs vies. À mes deux petites nièces adorées Lou et Maelle.

Je vous aime.

To Christopher,

My better half, my husband, my best friend, since we met you brightened up my life. Despite the distance that brings us apart during those last 4 years and half, you always have been there for me to keep me going through everything. You are my motivation in life and my muse. Finally, we are facing the final stretch before being established in Ireland where we met. A new beginning for a new step of our life together. I love you with all my heart, forever and always.

A mes parents,

Vous me soutenez depuis mon premier jour. Votre amour, votre foi en moi, vos encouragements à travers toutes les épreuves et votre motivation m'ont portée. Papa ton parcours professionnel est un exemple de persévérance, Maman ta rigueur et ton organisation sont un modèle pour moi. Je vous dois tout mon parcours scolaire et universitaire et bien plus encore...

Vous êtes un modèle de famille aimante et un modèle de couple uni pour Chris et moi. Je vous aime.

Je vous dédis ce travail.

Plan

LISTE DES ABREVIATIONS

ABSTRACT

INTRODUCTION

PATIENTS AND METHOD

RESULTS

- 1. Population and tumor characteristics description**
- 2. Median of follow up, overall survival**
- 3. Predictor risk factors for ipsilateral invasive recurrence within the whole population**
- 4. Predictor risk factors for ipsilateral invasive recurrence within sub group population with BCT and BCS treatment**
- 5. Margin index**

DISCUSSION AND CONCLUSION

REFERENCES

LISTE DES FIGURES

LISTE DES TABLEAUX

TABLE DES MATIERES

ANNEXES

Evaluation of predictor risk factors and calculation of a margin index for ipsilateral invasive recurrence following treatment of DCIS: a Fifteen year observational study.

M. BROOKS (MD) ¹, J.M. CLASSE (MD PhD) ², R. WERNERT (MD) ³, P. RARO (MD) ³, N. PAILLOCHER (MD) ³, L. CAMPION (PhD) ², Ph. DESCAMPS (MD PhD) ¹, A.S. OGER ³ (MD)

¹ Angers University Hospital department of Obstetrics and Gynecology

² Integrate Institute of Cancerology of Nantes, France, department of oncology surgery

³ Integrate Institute of Cancerology of Angers, France, department of oncology surgery

Corresponding author:

Marion BROOKS (MD)

CHU Angers department obstetrics and gynecology

4 rue Larrey

49100 ANGERS

Phone : +33 6 20 43 63 16

Email : marionrichard2207@gmail.com

ABSTRACT:

Background: The goal of ductal carcinoma in situ (DCIS) treatment is the local control of the disease, preventing or reducing potential occurrence of invasive breast cancer. The understanding of predictor risk factors for local invasive recurrence is a priority. The main objective was to evaluate patient and tumor characteristics as a risk for ipsilateral invasive recurrence. The second objective was calculation of a margin index to predict residual tumor on re-excision.

Patients and Method: Retrospectively, all female patients diagnosed and treated for DCIS from 2000 to 2015, from both Institut de Cancerologie of Angers and Nantes, were included. Risk for ipsilateral invasive recurrence following DCIS was evaluated according to patients and tumor characteristics. Margin index was calculated based on the original tumor size and the closest margin: *(closest margin / tumor size) in mm x 100*.

Results: The study retrospectively included 1388 patients with histologically confirmed DCIS. After five years of follow up, chance to survive without an ipsilateral invasive recurrence was 96.91%, IC 95% [95.64-97.81] A High nuclear grade, previous history of contralateral ductal carcinoma and breast conserving treatment were found to be predictor risk factors for local invasive recurrence in multivariate analysis HR1.96; IC 95% [1.06-3.62] $p=0.031$; HR2.83; IC 95% [1.09-7.37] $p=0.032$; HR2.22 IC 95% [1.02-4.83] $p=0.043$, respectively. Within the sub group population undergoing conserving treatment, only tendency was found for some factors to increase risk for LIR. A margin index of 5.6 was found to be the most suitable index to predict a risk for residual tumor on re-excision after the first surgery.

Key Words: DCIS; predictor risk factors, invasive recurrence, margin index

INTRODUCTION:

Ductal carcinoma in situ (DCIS) is a nonlethal pre malignant disease of the breast composed by a heterogeneous group of lesions. Since the introduction of screening mammography in the 1980s, detection of DCIS drastically increased and now represents nearly 20% of all newly diagnosed breast malignancies detected by mammography^{1, 2, 3}.

The purpose of treating DCIS is the local control of the disease, to prevent potential occurrence of an invasive breast cancer, as well as to maximize breast conservation and to maintain an acceptable cosmetic result. The natural history of DCIS remains unknown and some DCIS may turn into an invasive breast cancer.

There is currently no information to accurately identify women with a greater risk for subsequent disease recurrence which should be treated or followed more aggressively. Some factors, such as the tumor and patient's characteristics, biomarkers, and surgical margin status after breast conserving surgery (BCS) were found to be associated with a higher and or a lower risk of local invasive recurrence (LIR)^{1, 4, 5}. Within the past 20 years, randomized clinical trials have established that breast conserving surgery in addition to radiotherapy (BCT) may decrease the risk for a local recurrence^{6, 7}. It is therefore the gold standard for DCIS treatment. Yet, this treatment appears not suitable for all patients and offers no benefit to some. Discovering which specific features (from patient or from the original tumor) are predictors and increase the risk for LIR is a priority for DCIS treatment. The understanding of such factors, proven to be predictors and leading to a higher risk for LIR, could help health care providers to choose a more appropriate and tailored treatment for patients undergoing DCIS.

There is general agreement that clear margins decrease the risk of local recurrence for DCIS. However, there is no consensus on what is considered a clear margin following BCS^{5, 8, 9}. A previous study¹⁰ created a margin index among a population presenting an invasive breast

cancer, who benefitted from BCS. If this margin index is determined to be a better predictor of residual disease after BCS it will help in deciding whether or not to perform a re-excision. In light of the Zhang et al ¹¹ meta-analysis outcomes, the primary endpoint of the study was to evaluate if within the population diagnosed and treated for DCIS of the breast, some patient characteristics or tumor characteristics could be predictive risk factors for LIR. The second objective was to evaluate, among this same population, if the calculation of the margin index could accurately predict risk for residual tumors after surgery.

PATIENTS and METHOD:

Study design:

This retrospective observational study occurred on both campuses of the Institut de Cancerologie de l'Ouest (ICO) in Angers and Nantes. The study evaluated predictor risk factors for an invasive ipsilateral recurrence of DCIS between the first of January 2000 and the first of January 2015.

Population inclusion and exclusion:

Retrospectively, all female patients diagnosed and treated for DCIS were included. Every patient included in the study presented a histologically proved diagnosis of DCIS. Each case of DCIS was followed for diagnosis of a local invasive recurrence (LIR). Cases of (LIR) were defined as those diagnosed six months or more after DCIS diagnosis. Female patients younger than 18 years old or patients who underwent Lobular Carcinoma in situ were excluded from the study population.

In both institutes, patients received the surgical treatment (either BCS, BCS in addition to radiation therapy or radical mastectomy) or received only radiation therapy when surgery had been previously completed in another medical center. Patient medical records were the principal source of data. Data was collected through both Angers and Nantes ICO databases by researching for key words such as DCIS and invasive recurrence.

Follow up:

Follow up was through annual consultation, whether by the surgeon who performed the original surgery or the radiotherapist giving the radiotherapy. Annual follow up was

considered until July 2016. Each patient follow up duration was calculated in years from the date of diagnosis to the year last known alive. Each of the following events that occurred after the date of DCIS diagnosis was considered the first event: DCIS ipsilateral recurrence, LIR, occurrence of a second breast cancer, distant recurrence of the breast malignancy, and death of the patient. LIR or DCIS recurrence were always confirmed by a histological examination of the recurrence biopsy.

Description of tumor and patient's features analyzed:

During the primary part of the study, evaluation of each patient and tumor characteristics were made to estimate the risk for LIR following DCIS. Sub group analysis was done only on patients undergoing BCT or BCS treatment to evaluate survival without LIR and the predictive risk factors for LIR.

The patient characteristics analyzed were age, menopausal status and biomarkers. Patient age was defined as above or below 40 years old, menopausal status was whether patient was in menopause at the date of DCIS diagnosis or not. The biomarkers evaluated were the expression of estrogen receptors (positive versus negative), progesterone receptors (positive versus negative) and epidermal growth factor 2 (HER2) (positive versus negative). For each tumor characteristic, discrimination was made on nuclear grade (high versus intermediate and low), tumor size (≤ 20 millimeters (mm) or > 20 mm), comedonecrosis (positive or negative), focality (multifocal / multicentric versus unifocal), mode of detection (screening mammography or none), treatment received (lumpectomy alone, BCS with radiotherapy, mastectomy) and margin status. Even though there were no standardized definitions of a free margin, it was considered positive if ≤ 1 mm or involved and negative if > 1 mm or free of tumor. Regarding the lack of definition for tumor size, agreement was made that tumors measuring ≤ 20 mm were considered small.

Margin index calculation:

During the second part of the study, calculation of a margin index was done based on an equation including the original tumor size and the closest margin from each patient's first surgery: **(closest margin / tumor size) in mm x 100**. This calculation was made for every patient included in the study and within the sub group analysis for patients whom only benefitted from BCT or BCS treatment. For every patient, occurrence of a second surgery, and whether or not a residual tumor was found, was evaluated. Finally, a comparison was made between margin index and characteristics of potential second surgery to determine the best margin index value which could accurately predict if a residual tumor would be found during a second surgery. The feasibility of this index calculation as well as its reproducibility could avoid an unnecessary second surgical procedure.

Statistical analysis:

Quantitative parameters were described using their mean \pm standard deviation. Qualitative parameters were described using frequencies of their modalities. Time to invasive or DCIS relapse was defined as the time between date of diagnosis and date of the relapse event (or date of last visit if no recurrence occurred during the mean time). Survival curves were calculated using the Kaplan-Meier method. Groups of interest were compared using Student's t test for quantitative parameters, using the Pearson Chi-square test for qualitative parameters and a log-rank test for survival. Multivariate analysis was conducted if necessary using logistic regression (for the binary dependent variable) or Cox regression (time dependent variable). Every patient's characteristics or tumor's characteristics with a p value ≤ 0.15 in the univariate analysis were included in the multivariate analysis allowing for interaction. All tests were two-sided with p considered significant when $p < 5\%$. All

calculations were done using Stata SE 13.1 (StataCorp, College Station, Texas, USA) and SAS 9.4 (SAS Institute, Cary, NC, USA).

Both patients and the ethics committee (CNIL) received an informational letter to inform them about the ongoing study and for them to give their approval.

RESULTS :

1. Population and tumor characteristics description:

The study retrospectively included 1,388 patients, 784 patients from Angers and 604 patients from Nantes, with histologically proved DCIS. Populations were similar in both institutes. Characteristics of the population are described (Table 1). Out of the 1,388 patients included, 4.0% of the population presented a LIR, during follow up. An ipsilateral DCIS recurrence was found for 2.5% of the patients included (34 patients total). For 1,140 patients (82.1%), no event was reported through the end of their follow up.

Table I : Population characteristics

Population characteristics	Population (n= 1388)	Percentage (%)
RE status:		
Positive	344	24.8%
Negative	104	7.5%
Unknown	746	67.7%
RP status:		
Positive	269	19.4%
Negative	179	12.9%
Unknown	940	67.7%
HER 2 status:		
Positive	12	0.9%
Negative	43	3.1%
Unknown	1333	96.0%
Nuclear grade status:		
high	579	41.7%
moderate/low	765	55.1%
unknown	44	3.2%

Comedonecrosis status:

Positive	968	69.7%
Negative	277	20.0%
unknown	143	10.3%

Tumor size:

≤20mm	753	54.3%
>20mm	489	35.2%
Unknown	146	10.5%

Margin status:

Margin ≤ 1mm	556	40.0%
Margin > 1mm	799	57.6%
Unknown	33	2.4%

Treatment received:

Surgery alone	20	0.7%
BCS+ RT	921	66.4%
Mastectomy	447	32.2%
unknown	2	0.7%

Previous contralateral breast cancer:

Positive	88	6.3%
-----------------	----	------

RE: Receptor Estrogen; RP: Receptor Progesterone


RT: radiotherapy; BCS: Breast Conserving Surgery

CCI: Invasive Ductal of the breast; CLI: Lobular Carcinoma of the Breast

2. Median of follow up, overall survival:

The median of follow up was five years for every patient included in the study. After five years of follow up, the chance to survive without a LIR was 96.91%, CI 95% [95.64-97.81]. The median for LIR was five years (4.99 years). Within the sub group analysis for patients undergoing BCT or BCS treatment, median of follow up was five years. Within this population, the calculated survival rate without LIR after five years was 96.5% and after fifteen years of follow up was 87.5% (Figure 1).

Figure 1: Local invasive recurrence in BCS and BCT population (n= 941)



Interval calculated at 2.5 years, 7.5 years and 12 years.

3. Predictor risk factors for ipsilateral invasive recurrence within the whole population:

The univariate analysis for the whole population revealed three significant predictor risk factors for a LIR: a high nuclear grade of the tumor, previous treatment for a contralateral ductal carcinoma and treatment by BCT for this current episode of DCIS (Table 2). Predictor risk factors such as tumor size >20mm and /or patients who presented a micro invasive carcinoma (CCI) associated to the actual DCIS showed a tendency toward a risk for a LIR. However, they were not statistically significant: HR= 0.58; CI 95% [0.31- 1.09] p= 0.094 for large tumor size (> 20mm) and HR=2.07; CI 95% [0.93-4.61] p=0.072 for CCI associated to DCIS. (Table 2). After adjusting for the characteristics with a p value ≤ 0.15 (necrosis, tumor size, type of treatment, margin status, margin index and association with a micro invasive carcinoma), the multivariate analysis highlighted the same predictor risk factors to be significantly at risk for a LIR than those found from the univariate analysis. For high nuclear grade, patients with previous history of contralateral ductal carcinoma and patients treated by BCT, results were HR 1.96; CI 95% [1.06-3.62] p=0.031; HR 2.83; CI 95% [1.09-7.37] p=0.032; HR 2.22 CI 95% [1.02-4.83] p=0.043, respectively (Table 3).

Table II: Univariate analysis for Predictor Risk factors for an Ipsilateral Invasive Recurrence in population treated by mastectomy and BCT (n=1388)

Features evaluated	Hazard Ratio	Standard Error.	z	P> z	[95Conf.Interval]	
Estrogen No Vs Yes	1.420699	0.8548992	0.58	0.560	0.43681294.620711	
Progesterone No Vs Yes	2.391237	1.363917	1.53	0.126	0.7818319	7.313614
Nuclear Gr Low Vs High	0.5163464	0.1450223	-2.35	0.019	0.297763	0.895388
Necrosis No Vs Yes	0.775568	0.2913936	-0.68	0.499	0.3713723	1.619684
Tumor size > 20mm	0.5885844	0.1861794	-1.68	0.094	0.3166351	1.094104
Margin>1mm vs ≤1mm	0.8536121	0.242443	-0.56	0.577	0.4892177	1.489426
Mastectomy Vs BCT	0.4694626	0.1491378	-2.38	0.017	0.2518798	0.875001
Previous CCI No Vs Yes	0.4089302	0.1778129	-2.06	0.040	0.1743917	0.958898
Closest margin	1.022235	0.0462337	0.49	0.627	0.9355184	1.116989
Margin Index	0.9994585	0.0021481	-0.25	0.801	0.995257	1.003678

p ≤0.05 significant

Nuclear Gr= Nuclear grade

BCT =Breast Conserving Treatment

Table III: Multivariate analysis for predictor risk factors for ipsilateral invasive recurrence in population treated by mastectomy and BCT (n= 1388):

Predictor risk factors	Hazard Ratio	Standard Error	z	P> z	[95% Conf. Interval]
Year of diagnosis	0.9079171	0.0442558	-1.98	0.047	0.825191 0.998935
Nuclear Grade H Vs L	1.965106	0.6137648	2.16	0.031	1.06544 3.624459
Previous CCI	12.837402	1.382744	2.14	0.032	1.09171 7.374537
BCS Vs Mastectomy	2.226733	0.8802098	2.03	0.043	1.02611 4.83216

*Nuclear Grade H Vs L= Nuclear Grade High versus Low
 Previous CCI= Previous contralateral Ductal carcinoma
 BCS = Brest Conserving Surgery*

p ≤0.05 significant

4. Predictor risk factors for ipsilateral invasive recurrence

within sub group population with BCT and BCS treatment:

Outcomes from the univariate analysis within this sub group of the population did not find any predictor factors to be significantly at risk for LIR (Table 4). Only an increased tendency was found for negative progesterone receptor status, high nuclear grade, margin ≤1mm and previous history of carcinoma to be more at risk for LIR: HR 3.3 CI 95 [0.8-13.3] p=0.09; HR 0.5 CI 95 [0.3-0.04] p=0.07; HR 0.5 CI 95 [0.3-1.04] p=0.07; HR0.4 ci 95 [0.17-1.1] p= 0.09, respectively.

Table IV: Univariate Analysis on predictor risk factors for population with BCT and BCS treatment (n= 941):

Features evaluated	Hazard Ratio	Standard Error	z	P> z	[95% Conf. Interval]	
ER No Vs Yes	2.07519	1.478873	1.02	0.306	0.5133971	8.388072
PR No Vs Yes	3.331369	2.365134	1.70	0.090	0.8285235	13.39494
HER2 No Vs Yes	0.3481187	0.4264164	-0.86	0.389	0.0315556	3.840416
Nuclear Gr Low Vs High	0.5718561	0.176871	-1.81	0.071	0.3119007	0.048473
Necrosis No Vs Yes	0.6630466	0.2695903	-1.01	0.312	0.2988486	1.471082
Tumor size>20mm	0.7220691	0.3004924	-0.78	0.434	0.3194091	1.632339
Margin>1mm Vs≤1mm	0.5687377	0.177907	-1.80	0.071	0.3080686	1.049969
Previous CCI No Vs Yes	0.4478405	0.2132772	-1.69	0.092	0.1760969	1.138925
Closest margin	0.9872365	0.0490232	-0.26	0.796	0.8956804	1.088151
Margin Index	0.9983448	0.0025296	-0.65	0.513	0.9933992	1.003315

*ER= Estrogen Receptor
PR= Progesterone Receptor
Nuclear Gr= Nuclear Grade*

p ≤0.05 significant p<0.10 tendency

5. Margin index:

Evaluation on the risk to find a residual tumor after surgery and calculation of the margin index showed a mean tumor size for the entire population of 22mm with a mean closest margin of 3.22 mm. This resulted in a calculation of a mean margin index value of 43.37. Univariate analysis indicated that presence of comedonecrosis, large tumor size (>20mm),

presence of micro invasive ductal carcinoma and treatment by radical mastectomy (performed during second surgical procedure) were predictor risk factors for residual tumor on re-excision. Meanwhile, the multivariate analysis highlighted only the large tumor size (>20mm), the presence of comedonecrosis and the mastectomy to be predictor risk factors for finding residual tumors after the first surgical procedure. For comedonecrosis, large tumor size and mastectomy results were OR= 1.99; CI 95% [1.08-3.63] p=0.026; OR= 2.37; CI 95% [1.42-3.93] p= 0.001; OR= 4.88; CI 95% [2.89-8.24] p<0.00001, respectively. Within the sub group population undergoing BCT or BCS treatment, the mean closest margin was 3.82mm, mean tumor size was 15.6 mm which resulted in a calculation of a mean margin index value of 52.5. Within this same sub group population, a multivariate analysis found the presence of comedonecrosis and a larger tumor size > 20mm to be significant risk factors for finding residual tumors. Presence of comedonecrosis multiplies the risk of residual tumors by 2.06, and large tumor size (>20mm) multiplies the risk of residual tumors by 2.66. For comedonecrosis and large tumor size outcomes were OR 2.06 CI95[0.9-4.2] p=0.055; OR 2.66 CI 95 [1.4- 5.04] p= 0.003 respectively.

A margin index of 5.6 was found to be the most suitable index to predict a risk for residual tumor after the first surgery. According to this index value, the rate for false negatives was at its lowest (20%) which correlated to the lowest risk for false positive (55.2%). The rate of true positive and true negative for this value of margin index was 65.83%. Sensitivity and specificity for a 5.6 margin index were 80% and 44.72% respectively with a positive predictor value of 63.3% and a negative predictor value of 60% (Figure 2). Patients with a margin index higher than 5.6 were less likely to have residual tumor if re-excision was performed. Conversely, the presence of a residual tumor after the first surgical procedure was more likely if the patient presented a margin index lower than 5.6.

Figure 2: Determination of the Margin Index in global populations (mastectomy and BCT)




Figure legend: Operating characteristics:

- False Positive Rate -----
- Accuracy: True Negative and True Positive Rate -----
- False Negative Rate -----
- Youden Index -----

Determination of the margin index in comprehensive method included the lowest false positive rate with the most acceptable false negative rate.

DISCUSSION AND CONCLUSION

To our knowledge, this evaluation of predictors factors associated to a calculation of a margin index represent a unique way to determine predictor risk factors for LIR of DCIS and risk for residual tumor after the first surgical procedure.

Regarding the survival rate without LIR, our results showed only 3.5 % LIR after five years of follow up within the population whom benefitted from BCT or BCS treatment. After 15 years of follow up only 12.5 % of this precise population relapsed with a LIR. Our invasive recurrence rate concurred with those from the literature as Donker et al ¹² showed that populations whom benefitted from the same treatment (BCT) had a 15 years' invasive free local recurrence rate of 90%. In its own study, Falk et al ¹³ found that female patients with a primary diagnosis of DCIS had 11.2% risk to develop a subsequent breast malignancy within 10 years when treated by BCT. Our median of follow up of five years also concurred with these from Collins et al study ¹⁴.

According to our multivariate analysis within the whole population (patients treated by BCT and those treated by radical mastectomy), previous history of ductal carcinoma, high nuclear grade of the tumor and BCT treatment appear to be predictive risk factors for LIR. The high nuclear grade, being a predictor factor for local recurrence, has been previously evaluated in Collins et al study ¹⁴. However, in this study ¹⁴, even though there was a tendency for patients with a high nuclear grade of the tumor to present a local relapse, it was not statistically significant. Regarding the size of the tumor, our study highlighted that a larger size (>20mm) was associated with a tendency toward the risk for LIR, without being statistically significant unlike in the Collins et al study¹⁴.

Within our sub group population who benefitted from BCT analyzed for LIR, no predictor factors were found to be significantly at risk for LIR. Only high nuclear grade, negative progesterone receptor, or a previous history of breast carcinoma demonstrated a tendency

toward risk for LIR. Zhang's meta-analysis¹¹ highlighted this same tendency for LIR regarding the progesterone status, and the high nuclear grade. Others studies^{15, 16} presented biomarkers to be predictor factors for LIR such as HER2 overexpression and negative progesterone status. Except for a tendency toward risk to LIR for negative progesterone receptor in our sub group population analysis, our outcomes did not indicate biomarkers to be predictive risk factors for LIR. Yet, the lack of information for biomarkers status may constitute a bias regarding their involvement in this type of recurrence.

Evaluation of Zhang's study¹¹ and several other studies^{14, 17, 18} pointed out involved margin as a predictor risk factors for LIR. However, unlike in those studies^{11, 14, 17, 18}, neither in our whole population nor in our sub group of patients treated by BCT did the margin status represent a predictive risk factor for LIR. This can be explained by our mean closest margin of 3.82mm for patients treated by BCT or BCS which was considered as a clear margin in Zhang's meta-analysis¹¹. In this same meta-analysis¹¹, the other predictor risk factor found to be associated to an increased risk for LIR was the clinical detection of DCIS. In our study, this factor was not found to be predictor since more than 98% of the whole population presented a screening detection by mammography.

In a second part of our study, evaluation of a margin index was made, according to the same equation J.A. Margenthaler et al calculated in their own study¹⁰. Since no definition of a clear margin existed, they hypothesized that the optimum margin after BCS should depend on the original size of the tumor more so than on a standardized margin width. Therefore, they presented a new calculation of a margin index tailored to the relationship between the closest margin and the original size of the tumor. This margin index, being a better predictor of residual disease on re-excision than margin alone, will help to decide whether or not to perform a re-excision before adjuvant radiotherapy. Indeed, some studies such as the one from Jaffre et al¹⁹, evaluated the usefulness of a surgical re-excision after BCS in the case of

close or involved margin. Their outcomes demonstrated that there was no need to perform a systematic surgical re-excision for patients with close or involved margins. In Margenthaler's study, calculation of this margin index was done on a population undergoing invasive carcinoma of the breast stage I or II. As the index does not depend on histological features of the tumor but only on the closest margin and the original tumor size, extrapolation of the margin index was possible on our DCIS population. Our study showed that the most suitable margin index to predict risk for residual tumor was 5.6 with a false negative rate of 20%. This result corresponds to J.A Margenthaler study's outcomes which found an index value of five. According to both the J.A Margenthaler study and ours, the margin index appears to be a sensitive factor to help health care providers in their decision on whether or not to perform re-excision after the removal of the original tumor. Margin index's sensitivity for both studies, Margenthaler's and ours, was a similar 85% and 80% respectively. In the future, prospective controlled randomized trials should be done to more thoroughly evaluate its application in daily practice.

Our study presents some limitations. Firstly, the lack of data regarding the use of hormonal therapy that could influence the future development of invasive carcinoma. Indeed, the evaluation of biomarkers were not researched before 2010, consequently, patients treated before this year did not benefit from this medical treatment. Secondly, even though each patient included in the study presented a histological proved diagnosis of DCIS, this diagnosis was performed by pathologists from multiple institutions and hospitals which can lead to a certain degree of misclassification error, due to varying criteria among pathologists. Thirdly, our median follow-up of five years is relatively short and does not allow us to identify risk factors for LIR which could occur in a longer term interval. Last but not least, authors are aware that this study remains retrospective and observational, consequently, its results cannot influence clinical guidelines for DCIS treatment without supportive data from

controlled randomized trials. Despite those limitations, the study's strength lies in its large sample size population (1388 patients included). Moreover, the population included came from several hospitals and institutions from all France's north western region.

To conclude, our study suggested high nuclear grade, previous history of ductal carcinoma on the contralateral breast and patients treated with BCT to be predictor risk factors for LIR following DCIS. A 5.6 value for the margin index was the best value to identify risk for residual tumor after surgery. The understanding of those factors leading to a LIR is a priority for clinicians and surgeons. It will help them to provide the best tailored treatment for their patient, minimizing unnecessary procedures without reducing the local control of the tumor. Further studies should be done with larger sample size and longer follow up to support those outcomes.

REFERENCES :

1. Allegra CJ, Aberle DR, Ganschow P, Hahn SM, Lee CN, Millon-Underwood S, et al. National Institutes of Health State-of-the-Science Conference Statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22–24, 2009. *J Natl Cancer Inst.* 3 févr 2010;102(3):161-9.
2. Shah C, Wobb J, Manyam B, Kundu N, Arthur D, Wazer D, et al. Management of Ductal Carcinoma In Situ of the Breast: A Review. *JAMA Oncol.* 1 août 2016;2(8):1083-8.
3. Boxer MM, Delaney GP, Chua BH. A review of the management of ductal carcinoma in situ following breast conserving surgery. *Breast Edinb Scotl.* déc 2013;22(6):1019-25.
4. Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, et al. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. *J Clin Oncol Off J Am Soc Clin Oncol.* 15 avr 2001;19(8):2263-71.
5. Azu M, Abrahamse P, Katz SJ, Jagsi R, Morrow M. What is an adequate margin for breast-conserving surgery? Surgeon attitudes and correlates. *Ann Surg Oncol.* févr 2010;17(2):558-63.
6. Fisher ER, Dignam J. Pathologic findings from the national surgical adjuvant breast project (NSABP) eight-year update protocol B-17: intraductal carcinoma. *Cancer* 1999
7. Holmberg et al. Absolute risk reductions for local recurrence after postoperative radiotherapy after sector resection for ductal carcinoma in situ of the breast (2008).
8. Ward ST, Jones BG, Jewkes AJ. A two-millimetre free margin from invasive tumour minimises residual disease in breast-conserving surgery. *Int J Clin Pract.* nov 2010;64(12):1675-80.

9. Luini A, Rososchansky J, Gatti G, Zurrida S, Caldarella P, Viale G, et al. The surgical margin status after breast-conserving surgery: discussion of an open issue. *Breast Cancer Res Treat.* janv 2009;113(2):397-402.
10. Margenthaler JA, Gao F, Klimberg VS. Margin index: a new method for prediction of residual disease after breast-conserving surgery. *Ann Surg Oncol.* oct 2010;17(10):2696-701.
11. Zhang X, Dai H, Liu B, Song F, Chen K. Predictors for local invasive recurrence of ductal carcinoma in situ of the breast: a meta-analysis. *Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP.* janv 2016;25(1):19-28.
- 12: Donker M, Litiere S, Bijker N. Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial. *Journal of Clinical Oncology.* 2013;31(32):4054-9.
- 13: Falk RSCB, Hofvind S, Skaane P. Second events following ductal carcinoma in situ of the breast: a register-based cohort study. *Breast Cancer Research and Treatment.* 2011Mar;129(3):929-38.
- 14 : Collins LC, Achacoso N, Habel LA. Risk factors for non-invasive and invasive local recurrence in patients with ductal carcinoma in situ. *Breast Cancer Research and Treatment.* 2013;139(2):453-60.
- 15: Habel, Dailing, Weiss et al. Risk of recurrence after Ductal carcinoma in situ of the breast. *Cancer Epidemiol Biomarkers Prev* 7: 689- 696 (1998).
- 16: Han K, Nofech-Mozes S, Rakovitch. Expression of HER2neu in Ductal Carcinoma in situ is Associated with Local Recurrence. *Clinical Oncology.* 2012;24(3):183-9.

- 17: Houssami N, Macaskill P, Solin LJ. Meta-analysis of the impact of surgical margins on local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy. *European Journal of Cancer*. 2010;46(18):3219–32.
- 18 : Bijker, Meijnen, Rutgers et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. *J Clin Oncol*. 2006;24(21):3381-7.
- 19 : Jaffré I, Campion L, Classe J-M. Margin Width Should Not Still Enforce a Systematic Surgical Re-excision in the Conservative Treatment of Early Breast Infiltrative Ductal Carcinoma. *Annals of Surgical Oncology*. 2013Oct ;20(12):3831–8.
- 20: Kerlikowske K, Molinaro AM, Tlsty TD. Biomarker Expression and Risk of Subsequent Tumors After Initial Ductal Carcinoma In Situ Diagnosis. *JNCI Journal of the National Cancer Institute*. 2010;102(9):627–37.
- 21: Kataja V, Castiglione M. Primary breast cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. *Annals of Oncology*. 2009;20(Supplement 4):iv10–iv14.
- 22: Kong I, Narod S, Sengupta S. Age at diagnosis predicts local recurrence in women treated with breast-conserving surgery and postoperative radiation therapy for ductal carcinoma in situ: a population-based outcomes analysis. *Current Oncology*. 2013 Jul;21(1):96.
- 23: Li CI, Malone KE, Saltzman BS, Daling JR. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001. *Cancer*. 2006;106(10):2104–12.
- 24: Noh JM, Lee J, Kil W-H. HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy. *The Breast*. 2013 ;22(5):894–7.

25: Ringberg A, Nordgren H, Holmberg L. Histopathological risk factors for ipsilateral breast events after breast conserving treatment for ductal carcinoma in situ of the breast – Results from the Swedish randomised trial. *European Journal of Cancer*. 2007;43(2):291–8.

LISTE DES FIGURES

Figure 1 : Local invasive recurrence in BCS and BCT population (n= 941)	12
Figure 2: Determination of the Margin Index in global populations (mastectomy and BCT) .	18

LISTE DES TABLEAUX

Tableau I : Population characteristics	10-11
Tableau II: Univariate analysis for Predictor Risk factors for an Ipsilateral Invasive Recurrence in population treated by mastectomy and BCT (n=1388)	14
Tableau III: Multivariate analysis for predictor risk factors for ipsilateral invasive recurrence in population treated by mastectomy and BCT (n= 1388):	15
Tableau IV: Univariate Analysis on predictor risk factors for population with BCT and BCS treatment (n= 941):	16

TABLE DES MATIERES

LISTE DES ABREVIATIONS.....	VI
ABSTRACT	2
INTRODUCTION	3-4
PATIENTS AND METHOD	5-8
RESULTS	9-18
1.Population and tumor characteristics description	
2.Median of follow up, overall survival	
3.Predictor risk factors for ipsilateral invasive recurrence within the whole population	
4.Predictor risk factors for ipsilateral invasive recurrence within sub group population with BCT and BCS treatment	
5.Margin index	
DISCUSSION AND CONCLUSION	19-22
REFERENCES.....	23-26
LISTE DES FIGURES	27
LISTE DES TABLEAUX	28
TABLE DES MATIERES.....	29
ANNEXES.....	I-V

ANNEXES

Annexe 1: Ipsilateral Invasive Recurrence Free Survey in whole population (mastectomy + BCT and BCS population)

Time (years)	Beg.		Survivor	Standard	[95% Conf. Int.]	
	Total	Fail	Function	Error		
1	1193	3	0.9975	0.0014	0.9922	0.9992
2	1186	8	0.9908	0.0028	0.9834	0.9949
3	1112	5	0.9863	0.0034	0.9778	0.9916
4	972	7	0.9793	0.0043	0.9689	0.9862
5	857	9	0.9691	0.0054	0.9564	0.9781
6	738	3	0.9651	0.0059	0.9516	0.9750
7	628	2	0.9621	0.0062	0.9477	0.9725
8	508	2	0.9583	0.0068	0.9428	0.9697
9	431	4	0.9495	0.0080	0.9312	0.9630
10	370	3	0.9418	0.0091	0.9211	0.9572
11	290	5	0.9256	0.0115	0.8996	0.9451
12	217	3	0.9130	0.0134	0.8826	0.9358
13	165	1	0.9075	0.0144	0.8747	0.9320
15	126	0	0.9075	0.0144	0.8747	0.9320

Annexe 2: survival rate without invasive recurrence for population with BCT and BCS treatment
(n=941):

Time (years)	Beginner Total	Fail	Survivor Function	Standard Error	[95% Conf. Int.]	
1	834	2	0.9976	0.0017	0.9905	0.9994
2	821	7	0.9892	0.0036	0.9793	0.9944
3	762	5	0.9827	0.0046	0.9709	0.9897
4	659	4	0.9768	0.0054	0.9634	0.9853
5	571	7	0.9650	0.0070	0.9483	0.9763
6	481	2	0.9610	0.0075	0.9432	0.9732
7	408	2	0.9563	0.0082	0.9371	0.9697
8	323	1	0.9533	0.0086	0.9330	0.9676
9	269	4	0.9393	0.0110	0.9136	0.9575
10	227	2	0.9311	0.0123	0.9024	0.9516
11	174	5	0.9045	0.0168	0.8657	0.9325
12	130	3	0.8842	0.0201	0.8381	0.9179
13	96	1	0.8750	0.0219	0.8248	0.9116
14	95	0	0.8750	0.0219	0.8248	0.9116
15	71	0	0.8750	0.0219	0.8248	0.9116


Annexe 3: Specificity and Sensibility for Margin Index value of 5.6 for patients with known results for residual tumor during second surgery (n=401)

True D defined as residual Tumor = YES		[95% Conf. Inter.]
--	--	--------------------

Sensitivity	Pr (+ D) 80.00%	[76.08% - 83.92%]
Specificity	Pr(- ~D) 44.72%	[39.85% - 49.59%]
Positive predictive value	Pr (D +) 68.33%	[63.77% - 72.88%]
Negative predictive value	Pr(~D -) 60.00%	[55.21% - 64.79%]

Prevalence	Pr(D) 59.85%	[55.05% - 64.65%]
------------	--------------	-------------------

Annexe 4: Risk for an Invasive Ipsilateral Recurrence in Years for whole population (Mastectomy + BCT and BCS population)



Interval calculated at 2.5 years, 7.5 years and 12 years

Annexe 5: Mutlivariate analysis for BCT and BCS treatment population to find residual tumor after first surgical procedure.

Residual tumor	Odds Ratio	Standard Error	z	P> z	[95% Conf. Interval]	
Necrosis presence	2.058516	0.7733823	1.92	0.055	0.9857316	4.298825
Tumor size >20mm	2.659539	0.8676407	3.00	0.003	1.403177	5.040806

p ≤ 0.05 significant

Evaluation des facteurs de risque péjoratifs et calcul d'un index de marge dans le risque de récurrence infiltrante homolatérale après traitement d'un Carcinome in Situ du sein : une étude observationnelle de 15 ans.

RÉSUMÉ

Introduction : Le but du traitement des carcinomes canauxaires in situ (CCIS) est le contrôle local de la maladie, afin de prévenir le risque de survenue d'une récurrence infiltrante. La connaissance des facteurs de risque de récurrence locale invasive apparaît de fait comme une priorité. L'objectif principal de l'étude était l'évaluation de ces facteurs de risque de récurrence infiltrante au sein des caractéristiques propre au patient et à sa tumeur initiale. L'objectif secondaire était l'élaboration d'un index de marge prédisant le risque de reliquat tumoral avant une éventuelle décision de reprise chirurgicale.

Sujets et Méthodes : Rétrospectivement, toutes les patientes diagnostiquées et traitées pour un CCIS entre 2000 et 2015 entre les centres anti cancer de Angers et de Nantes étaient incluses dans l'étude. Le risque de récurrence infiltrante homolatérale était évalué selon l'étude des caractéristiques du patient et de la tumeur. L'index de marge était calculé selon le rapport entre la taille de la tumeur initiale et la taille de la marge la plus proche de la tumeur selon l'équation : (marge la plus proche/taille de la tumeur) en mm x100.

Résultats : L'étude a permis l'inclusion de 1388 patientes toutes présentant un diagnostic histologique de CCIS. Après un suivi de 5 ans, la chance de survie sans récurrence infiltrante était de 96.91%, IC 95% [95.64-97.81]. Le grade nucléaire élevé, l'antécédent de cancer du sein controlatéral et le traitement conservateur étaient retrouvés comme étant significativement prédictifs d'un risque de récurrence infiltrante homolatérale en analyse multivariée, respectivement : HR1.96 ; IC 95% [1.06-3.62] p=0.031 ; HR2.83 ; IC 95% [1.09-7.37] p=0.032; HR2.22 IC 95% [1.02-4.83] p=0.043. Au sein de l'analyse en sous-groupe pour la population ayant bénéficié d'un traitement conservateur, seule une tendance était retrouvée comme a risque de récurrence locale infiltrante sur certains facteurs. La valeur de 5.6 pour l'index de marge était la plus performante pour prédire le risque de reliquat tumoral sur une ré excision chirurgicale pratiquée après chirurgie conservatrice première.

Mots-clés : CCIS, facteurs de risque péjoratifs, récurrence infiltrante, index de marge

Evaluation of predictor risk factors and calculation of a margin index for ipsilateral invasive recurrence following treatment of DCIS: a Fifteen year observational study.

ABSTRACT

Background: The goal of ductal carcinoma in situ (DCIS) treatment is the local control of the disease, preventing or reducing potential occurrence of invasive breast cancer. The understanding of predictor risk factors for local invasive recurrence is a priority. The main objective was to evaluate patient and tumor characteristics as a risk for ipsilateral invasive recurrence. The second objective was calculation of a margin index to predict residual tumor on re-excision.

Patients and Method: Retrospectively, all female patients diagnosed and treated for DCIS from 2000 to 2015, from both Institut de Cancerologie of Angers and Nantes, were included. Risk for ipsilateral invasive recurrence following DCIS was evaluated according to patients and tumor characteristics. Margin index was calculated based on the original tumor size and the closest margin: (closest margin / tumor size) in mm x 100.

Results: The study retrospectively included 1388 patients with histologically confirmed DCIS. After five years of follow up, chance to survive without an ipsilateral invasive recurrence was 96.91%, IC 95% [95.64-97.81] A High nuclear grade, previous history of contralateral ductal carcinoma and breast conserving treatment were found to be predictive risk factors for local invasive recurrence in multivariate analysis HR1.96; IC 95% [1.06-3.62] p=0.031; HR2.83; IC 95% [1.09-7.37] p=0.032; HR2.22 IC 95% [1.02-4.83] p=0.043, respectively. Within the sub group population undergoing conserving treatment, only tendency was found for some factors to increase risk for LIR. A margin index of 5.6 was found to be the most suitable index to predict a risk for residual tumor on re-excision after the first surgery.

Keywords: DCIS; predictor risk factors, invasive recurrence, margin index